Drug Combinations and Uses in Treating a Coughing Condition
The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.
1 - 82 . (canceled)
83 . A composition comprising a methylxanthine and a plurality of additional therapeutic compounds having antitusive activity.
84 . The composition according to claim 83 , wherein the methylxanthine includes Aminophylline, Caffeine, IBMX, Paraxanthine, Pentoxifylline, Theobromine, Theophylline, Xanthine, or any combination thereof.
85 . The composition according to claim 83 , wherein the plurality of therapeutic compounds having antitusive activity includes a non-opiate anti-tussive agent, an opiate anti-tussive agent, a decongestant, an expectorant, a mucolytic agent, an anti-histamine, a non-steroidal anti-inflammatory drug (NSAID), a neuropathic pain agent, a terpene, an ACE inhibitor, an angiotensin II receptor antagonist or any combination thereof.
86 . The composition according to claim 83 , wherein the pharmaceutical composition reduces an unwanted side.
87 . The composition according to claim 86 , wherein the unwanted side includes sedation, cognitive fogging, dizziness, drowsiness, postural hypertension, coordination problems, weakness, tremors, respiratory depression, psychotropic effects, sleep disturbances, unwanted waitfulness, CNS stimulation, weight gain, appetite change, change in sexual function, constipation, dry mouth, gut erosion, gastric ulcerations, renal inflammation, cardiovascular hypertension, cardiovascular stimulation, hyperchlimina, not going into public, chest pain, stress incontinence, or any combination thereof.
88 . The composition according to claim 83 , wherein the antitussive activity reduces a symptom associated with a coughing condition.
87 . The composition according to claim 88 , wherein the antitussive activity reduces a symptom associated with a coughing condition by at least 10%.
88 . The composition according to claim 88 , wherein the symptom includes the frequency of a cough, the severity of a cough, the volume or noise level of a cough, hoarseness, sore throat, breathing difficulty, respiratory congestion, wheezing, respiratory constriction, respiratory inflammation, muscle spasms associated with a cough, phlegm production, fainting, insomnia, vomiting, subconjunctival hemorrhage (red eye), cough defecation, cough urination, abdominal hernia, pelvic hernia, costochondritis, or lower rib fracture.
89 . The composition according to claim 83 , wherein the antitussive activity suppresses a vagal nerve function associated with a cough.
90 . The composition according to claim 89 , wherein the antitussive activity suppresses a vagal nerve function associated with a cough by at least 10%.
91 . A method of treating a coughing condition in an individual, the method comprising the step of administering a composition according to claim 83 , wherein administration reduces a symptom associated with the coughing condition.
92 . The method according to claim 91 , wherein the coughing condition comprises an acute coughing condition.
93 . The method according to claim 91 , wherein the coughing condition comprises a subacute coughing condition.
94 . The method according to claim 91 , wherein the coughing condition comprises a chronic coughing condition.
95 . The method according to claim 91 , wherein the coughing condition comprises a non-productive coughing condition.
96 . The method according to claim 91 , wherein the coughing condition comprises a productive coughing condition.
97 . The method according to claim 91 , wherein the coughing condition comprises a cough associated with a disease or disorder.
98 . The method according to claim 97 , wherein the disease or disorder is an asthma, an atopic cough a bronchitis, a gastroesophageal reflux disease (GERD), an infection of the respiratory tract, an inflammation, a medication, a pollutant, a post-nasal drip, a smoking event, a vagal nerve irritation, a diseases of the external auditory canal, a lung disease, a lung tumor, a habit cough, a tic, a Tourette syndrome, a cardiovascular disease, or a post-infectious cough.
99 . The method according to claim 91 , wherein administration of the pharmaceutical composition reduces an unwanted side.
100 . The method according to claim 99 , wherein the unwanted side includes sedation, cognitive fogging, dizziness, drowsiness, postural hypertension, coordination problems, weakness, tremors, respiratory depression, psychotropic effects, sleep disturbances, unwanted waitfulness, CNS stimulation, weight gain, appetite change, change in sexual function, constipation, dry mouth, gut erosion, gastric ulcerations, renal inflammation, cardiovascular hypertension, cardiovascular stimulation, hyperchlimina, not going into public, chest pain, stress incontinence, or any combination thereof.
101 . The method according to claim 91 , wherein the symptom includes coughing, hoarseness, sore throat, breathing difficulty, respiratory congestion, wheezing, respiratory constriction, respiratory inflammation, muscle spasms associated with a cough, phlegm production, fainting, insomnia, vomiting, subconjunctival hemorrhage (red eye), cough defecation, cough urination, abdominal hernia, pelvic hernia, costochondritis, lower rib fracture, or any combination thereof.